Blood Cancer News and Research RSS Feed - Blood Cancer News and Research

Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

Cell Therapy Catapult becomes Cell and Gene Therapy Catapult

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the official change of its name to the Cell and Gene Therapy Catapult. [More]
ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

ST Asia signs licensing deal with PharmaMar to distribute new multiple myeloma drug in South East Asia

International biopharmaceutical company Specialised Therapeutics Asia will supply and distribute a novel oncology drug candidate throughout South East Asia, following an exclusive licensing deal with European pharmaceutical company PharmaMar. [More]
Simple blood test could predict relapse in AML patients

Simple blood test could predict relapse in AML patients

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London. [More]
Hhex protein could be key target for new therapies to cure leukaemia

Hhex protein could be key target for new therapies to cure leukaemia

Melbourne researchers have showed that they can stop leukaemia in its tracks by targeting a protein that puts the handbrake on cancer cell growth. [More]
Researchers identify origins of aggressive childhood lymphoma

Researchers identify origins of aggressive childhood lymphoma

The origins of a type of aggressive childhood lymphoma have been found, giving hope that new drugs could be designed to prevent the disease coming back after treatment. [More]
Drugs that block KDM4C and PRMT1 genes could be effective in treating AML

Drugs that block KDM4C and PRMT1 genes could be effective in treating AML

Two genes have been identified that are critical to the development of the biggest leukaemia killer, acute myeloid leukaemia (AML). Researchers at King’s College London found that drugs that selectively block these genes could be highly effective in treating this type of leukaemia. [More]
McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers take a giant leap in detecting early stages of leukemia

McMaster University researchers have taken a giant leap in identifying the early stages of a deadly cancer and predicting how it will develop in individuals. [More]
Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan introduces new tissue typing method that could revolutionise stem cell transplantation

Anthony Nolan has today launched a new tissue typing method that could significantly improve stem cell transplant outcomes. [More]
New TAU study offers tangible hope of curing Mantle Cell Lymphoma

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

With a median survival rate of just five to seven years, Mantle Cell Lymphoma (MCL) is considered the most aggressive known blood cancer -- and available therapies are scarce. Three thousand Americans are diagnosed with MCL every year, and despite progress in personalized therapies to treat metastases elsewhere in the body, systemic therapeutic drug delivery to cancerous blood cells continues to challenge the world of cancer research. [More]
Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Wnt5a protein acts on tumor-surface proteins to accelerate spread of CLL cells

Building upon previous research, scientists at University of California, San Diego School of Medicine and UC San Diego Moores Cancer report that a protein called Wnt5a acts on a pair of tumor-surface proteins, called ROR1 and ROR2, to accelerate the proliferation and spread of chronic lymphocytic leukemia (CLL) cells, the most common form of blood cancer in adults. [More]
Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Innovative Phase II trial evaluates effectiveness of diabetes medication for lymphoma

Cancer, it could be said, grows like a weed: rapidly, invasively, and with devastating impact on the place it infests. Also like a weed, cancer can't grow on its own — it needs nourishment, which it drains from the human body, just as weeds take nutrients in the soil away from other plants. [More]
Researchers find new significant link between NPM protein and development of AML

Researchers find new significant link between NPM protein and development of AML

A team of researchers from the National University of Singapore has found a new significant correlation between the protein nucleophosmin (NPM) and the development of an aggressive form of blood cancer called acute myeloid leukemia (AML). [More]

Researchers identify genes that act as brakes to stop development of aggressive type of leukaemia

Genes that act as brakes to stop the development of an aggressive form of leukaemia have been identified by researchers. [More]
Faulty gene function responsible for reducing survival times of leukaemia patients

Faulty gene function responsible for reducing survival times of leukaemia patients

Researchers have identified a genetic fault in some leukaemia patients that could be responsible for halving survival times after diagnosis compared to patients without the fault – an average reduction from 16 years to seven years. T [More]
New approaches to treating leukemia, lymphoma and myeloma

New approaches to treating leukemia, lymphoma and myeloma

New, highly targeted treatment approaches for leukemia, lymphoma, and myeloma to be presented today at the 57th American Society of Hematology Annual Meeting and Exposition represent a tremendous expansion of oral and intravenous therapy options for patients with blood cancers. [More]
Yale study identifies how myeloma cells escape treatment

Yale study identifies how myeloma cells escape treatment

One of the biggest questions about the treatment of multiple myeloma, a form of blood cancer, is why nearly all patients treated with current therapies eventually suffer relapse. A Yale Cancer Center study may have solved this mystery by identifying how cancer cells escape treatment, leading to recurrence. [More]
Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

Experimental gene therapy may improve health outcomes for patients with some forms of blood disorders

New research adds to a growing body of evidence that gene therapy, an experimental technique that involves correcting or replacing a person's mutated or malfunctioning genes, may improve health outcomes for patients with inherited bleeding and immune disorders as well as some forms of blood cancer. [More]
FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

FDA grants approval for Empliciti (elotuzumab) to treat patients with multiple myeloma

Today the U.S. Food and Drug Administration granted approval for Empliciti (elotuzumab) in combination with two other therapies to treat people with multiple myeloma who have received one to three prior medications. [More]
Scientists map out genes that keep cancer cells alive

Scientists map out genes that keep cancer cells alive

Scientists have mapped out the genes that keep our cells alive, creating a long-awaited foothold for understanding how our genome works and which genes are crucial in disease like cancer. [More]

SkylineDx's MMprofiler receives CE-IVD certification

SkylineDx, today announced they have received CE-IVD registration from the European Competent Authority (Ministry of Health) for the MMprofiler, the company's prognostic test to determine the level of risk of a patient with multiple myeloma (MM). [More]
Advertisement
Advertisement